Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ABEO

Abeona Therapeutics Inc

May 03 • 04:00PM ET

4.60

Dollar change +0.53
Percentage change 13.02	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF ITOT IWC SURI DFAS IBRN AVSC

Index	-	P/E	-	EPS (ttm)	-2.59	Insider Own	5.40%	Shs Outstand	26.52M	Perf Week	41.10%
Market Cap	125.86M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	3.12%	Shs Float	25.88M	Perf Month	-40.26%
Income	-54.19M	PEG	-	EPS next Q	-0.51	Inst Own	52.12%	Short Float	7.97%	Perf Quarter	4.07%
Sales	3.50M	P/S	35.96	EPS this Y	15.55%	Inst Trans	22.75%	Short Ratio	3.48	Perf Half Y	20.10%
Book/sh	0.56	P/B	8.23	EPS next Y	11.23%	ROA	-84.53%	Short Interest	2.06M	Perf Year	48.39%
Cash/sh	1.92	P/C	2.39	EPS next 5Y	-	ROE	-260.60%	52W Range	2.83 - 9.01	Perf YTD	-8.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	38.92%	ROI	-281.82%	52W High	-48.95%	Beta	1.51
Dividend TTM	-	Quick Ratio	4.15	Sales past 5Y	-15.07%	Gross Margin	8.63%	52W Low	62.54%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	4.15	EPS Y/Y TTM	60.51%	Oper. Margin	-1377.14%	RSI (14)	39.51	Volatility	16.22% 10.01%
Employees	84	Debt/Eq	0.36	Sales Y/Y TTM	147.52%	Profit Margin	-1548.23%	Recom	1.00	Target Price	19.50
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	-920.75%	Payout	-	Rel Volume	4.53	Prev Close	4.07
Sales Surprise	-	EPS Surprise	-25.53%	Sales Q/Q	-100.00%	Earnings	Mar 18 BMO	Avg Volume	593.03K	Price	4.60
SMA20	-23.00%	SMA50	-34.16%	SMA200	-8.72%	Trades		Volume	2,683,913	Change	13.02%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23
Jul-18-17	Reiterated	Maxim Group	Buy	$14 → $17
Jun-22-17	Resumed	Jefferies	Buy	$22
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy	$8 → $14

Show Previous Ratings

May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	Loading…
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM	Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM	UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM	US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM	Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
Apr-01-24 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.48%
Mar-19-24 06:53AM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +8.30%
05:31AM	Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results (GuruFocus.com)
Mar-18-24 07:30AM	Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections (GlobeNewswire) -19.00%
Mar-05-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.32%
05:52AM	Loading…
Feb-15-24 05:52AM	Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc (GuruFocus.com) +5.53%
Feb-01-24 04:05PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65%
07:30AM	Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) (GlobeNewswire)
Jan-08-24 07:30AM	Abeona Therapeutics Announces $50 Million Credit Facility (GlobeNewswire)
Dec-15-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-23 07:30AM	Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) (GlobeNewswire) +11.60%
Nov-17-23 10:09AM	Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:29AM	Q3 2023 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM	Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ... (GuruFocus.com) +10.02%
07:41AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-01-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
07:30AM	Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer (GlobeNewswire)
07:30AM	Loading…
Sep-07-23 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 07:30AM	Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission (GlobeNewswire) +5.60%
Aug-11-23 07:41AM	ABEO: On Track to File BLA in 3Q23... (Zacks)
Aug-08-23 08:27AM	Abeona Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Abeona Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 07:30AM	Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 (GlobeNewswire) +5.37%
Jul-19-23 08:30AM	Abeona Therapeutics Joins Rare Disease Company Coalition (GlobeNewswire)
Jul-07-23 08:30AM	Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-03-23 08:45AM	Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +6.95%
Jun-09-23 07:30AM	Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101 (GlobeNewswire)
Jun-01-23 07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 08:00AM	ABEO: Additional Phase 3 VIITAL Data Presented at ISID Meeting (Zacks Small Cap Research)
May-25-23 12:27AM	Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call (Thomson Reuters StreetEvents)
May-22-23 07:30AM	Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 (GlobeNewswire)
May-16-23 09:00AM	Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
May-13-23 08:15AM	Abeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022) (Simply Wall St.)
May-11-23 07:54AM	Abeona Therapeutics: Q1 Earnings Snapshot (AP Finance) -7.19%
07:30AM	Abeona Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Abeona Therapeutics Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting (GlobeNewswire)
Apr-18-23 07:15AM	ABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases (Zacks Small Cap Research)
Apr-10-23 07:30AM	Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
Mar-31-23 06:22AM	Companies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Risky (Simply Wall St.)
Mar-29-23 07:30AM	Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants (GlobeNewswire) +11.52%
Mar-16-23 07:30AM	Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting (GlobeNewswire)
Mar-14-23 07:30AM	Abeona Therapeutics Announces Update on AAV Ophthalmology Program (GlobeNewswire)
Nov-14-22 07:30AM	Abeona Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.47%
Nov-08-22 02:28PM	Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario' (Benzinga)
Nov-03-22 12:44PM	Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder (Benzinga) -13.23%
07:31AM	Abeona Therapeutics Announces $35 Million Private Placement Financing (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 (GlobeNewswire)
Oct-19-22 07:30AM	Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire) -8.09%
Oct-04-22 07:30AM	Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Sep-22-22 07:30AM	Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -9.22%
Sep-13-22 07:30AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:48AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-11-22 07:30AM	Abeona Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +12.02%
Jul-20-22 07:30AM	Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-24-22 10:08AM	F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm (Zacks) -8.94%
Jun-13-22 01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy (Zacks) -6.18%
Jun-10-22 03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy (Zacks)
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy (Zacks) +8.49%
Jun-06-22 02:04PM	AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half (Zacks)
07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -7.84%
May-31-22 02:27PM	Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe (Zacks)
May-25-22 02:29PM	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease (Zacks)
May-23-22 03:32PM	Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal (Zacks)
May-19-22 03:02PM	Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops (Zacks)
07:30AM	Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -7.03%
11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks)
May-17-22 09:27AM	AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug (Zacks)
08:00AM	Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics (GlobeNewswire)
May-13-22 07:30AM	Abeona Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 02:47PM	AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals (Zacks) +15.09%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates (Zacks) -14.69%
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates (Zacks)
11:37AM	Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down (Zacks)
May-06-22 03:48PM	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.37%
03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates (Zacks)
May-04-22 07:30AM	Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates (GlobeNewswire)
May-03-22 07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier (American City Business Journals)
Apr-29-22 09:00AM	Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) -7.07%
07:30AM	Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire)
Apr-19-22 10:51AM	Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth? (Simply Wall St.)
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire)
Mar-28-22 11:20AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit (GlobeNewswire)
Mar-14-22 07:30AM	Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL Study of EB-101 in RDEB (GlobeNewswire)
Jan-25-22 10:00AM	Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing (Zacks) +7.57%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Charles Faith L.	Director	Apr 26 '24	Buy	3.28	7,550	24,764	78,323	Apr 29 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Apr 25 '24	Buy	3.20	10,000	32,000	538,260	Apr 29 08:30 AM
O'Malley Brendan M.	SVP, General Counsel	Apr 25 '24	Buy	3.24	8,600	27,864	188,718	Apr 26 08:30 AM
Vazzano Joseph Walter	Chief Financial Officer	Apr 25 '24	Buy	3.14	5,608	17,609	233,868	Apr 26 08:30 AM
Seshadri Vishwas	Chief Executive Officer	Feb 06 '24	Buy	4.39	20,000	87,800	528,260	Feb 07 08:30 AM
Alvino Mark	Director	Jan 17 '24	Sale	5.11	7,084	36,199	62,816	Jan 22 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 27 '23	Buy	4.07	20,000	81,400	521,731	Sep 29 07:30 AM
Charles Faith L.	Director	Sep 27 '23	Sale	4.91	8,330	40,924	70,773	Sep 29 04:30 PM
Alland Leila	Director	Sep 27 '23	Sale	3.90	7,246	28,270	71,857	Sep 29 04:30 PM
Alvino Mark	Director	Sep 27 '23	Sale	3.91	6,316	24,724	69,900	Sep 29 04:30 PM
Silverstein Christine Berni	Director	Sep 27 '23	Sale	3.91	6,330	24,721	87,884	Sep 29 04:30 PM
Amoroso Michael	Director	Sep 27 '23	Sale	3.91	5,508	21,542	108,957	Sep 29 04:30 PM
Amoroso Michael	Director	Sep 20 '23	Sale	3.90	327	1,275	114,465	Sep 22 04:05 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 19 '23	Buy	3.82	3,000	11,458	238,179	Sep 20 09:00 AM
O'Malley Brendan M.	SVP, General Counsel	Sep 18 '23	Buy	3.80	3,000	11,400	187,421	Sep 19 09:00 AM
Amoroso Michael	Director	Jun 20 '23	Sale	4.45	338	1,504	114,792	Jun 21 04:05 PM

Open in Screener

PMVP

PMV Pharmaceuticals Inc

May 03 • 04:00PM ET

1.99

Dollar change +0.12
Percentage change 6.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PMVP PMV Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC AVSC VTWV

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	20.87%	Shs Outstand	51.45M	Perf Week	13.71%
Market Cap	102.37M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-0.81%	Shs Float	40.71M	Perf Month	24.37%
Income	-68.96M	PEG	-	EPS next Q	-0.36	Inst Own	88.00%	Short Float	6.83%	Perf Quarter	11.80%
Sales	0.00M	P/S	-	EPS this Y	4.17%	Inst Trans	-5.22%	Short Ratio	4.93	Perf Half Y	0.51%
Book/sh	4.39	P/B	0.45	EPS next Y	-3.04%	ROA	-26.40%	Short Interest	2.78M	Perf Year	-58.71%
Cash/sh	3.96	P/C	0.50	EPS next 5Y	23.10%	ROE	-29.24%	52W Range	1.17 - 9.72	Perf YTD	-35.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-28.63%	ROI	-28.96%	52W High	-79.53%	Beta	1.55
Dividend TTM	-	Quick Ratio	14.78	Sales past 5Y	0.00%	Gross Margin	-	52W Low	69.36%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	14.78	EPS Y/Y TTM	10.20%	Oper. Margin	0.00%	RSI (14)	66.81	Volatility	5.28% 6.12%
Employees	63	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	5.67
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	27.64%	Payout	-	Rel Volume	2.25	Prev Close	1.87
Sales Surprise	-	EPS Surprise	18.92%	Sales Q/Q	-	Earnings	Feb 29 AMC	Avg Volume	564.41K	Price	1.99
SMA20	18.17%	SMA50	15.91%	SMA200	-41.36%	Trades		Volume	1,272,552	Change	6.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-24	Initiated	Jefferies	Buy	$5
Dec-27-23	Initiated	Ladenburg Thalmann	Buy	$7
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform	$30
Sep-22-21	Upgrade	Goldman	Neutral → Buy	$35 → $43
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy	$56
Jul-29-21	Initiated	H.C. Wainwright	Buy	$63
Oct-20-20	Initiated	Goldman	Neutral	$34
Oct-20-20	Initiated	Evercore ISI	Outperform	$60
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	BofA Securities	Buy	$42

Show Previous Ratings

Mar-27-24 08:00AM	PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors (GlobeNewswire)
Mar-18-24 04:01PM	PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer (GlobeNewswire) -5.11%
Mar-01-24 10:21AM	PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 04:01PM	PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-26-24 08:00AM	PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +7.78%
04:01PM	Loading…
Jan-18-24 04:01PM	PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway (GlobeNewswire) -5.76%
Jan-05-24 04:01PM	PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development (GlobeNewswire) -5.94%
Nov-09-23 09:41AM	PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
08:00AM	PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-16-23 09:35AM	PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.00%
Oct-12-23 12:30PM	PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation (GlobeNewswire) -47.58%
Oct-11-23 12:00PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar (GlobeNewswire) -26.01%
Oct-06-23 09:55AM	Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High? (Zacks) +6.62%
Sep-20-23 04:05PM	PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +9.62%
Aug-30-23 09:55AM	Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet (Zacks)
09:55AM	Loading…
Aug-29-23 09:55AM	PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Aug-09-23 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +27.69%
Jun-06-23 04:01PM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +7.56%
May-10-23 08:00AM	PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) +8.33%
Apr-14-23 11:51AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-01-23 08:00AM	PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) -14.15%
Feb-28-23 04:05PM	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March (GlobeNewswire)
Dec-08-22 09:55AM	Does PMV Pharmaceuticals, Inc. (PMVP) Have the Potential to Rally 267% as Wall Street Analysts Expect? (Zacks)
Nov-22-22 08:00AM	PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) +5.02%
Nov-17-22 06:18PM	15 Most Shorted Stocks Right Now (Insider Monkey)
Nov-08-22 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire)
Nov-05-22 09:39AM	We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-04-22 08:00AM	PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors (GlobeNewswire)
Oct-11-22 12:00PM	PMV Pharmaceuticals, Inc. (PMVP) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey)
08:00AM	Loading…
Aug-09-22 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) -8.06%
Jul-19-22 09:26AM	10 Most Shorted Stocks to Watch in July (Insider Monkey) +5.81%
Jul-18-22 10:47AM	PMV Pharma, Merck Ink Clinical Trial Collaboration For Combination Study In Solid Tumors (Benzinga) -9.52%
08:00AM	PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
Jun-08-22 08:00AM	PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.71%
Jun-07-22 12:00PM	PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation (GlobeNewswire) -21.70%
May-29-22 08:26AM	We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate (Simply Wall St.)
May-26-22 05:05PM	PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-20-22 03:04PM	Pennsylvania Biotech Center's economic impact grows to $7B as it expands in Bucks County, report finds (American City Business Journals)
May-10-22 07:30AM	PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights (GlobeNewswire) +9.66%
Apr-27-22 10:30AM	PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Mar-01-22 07:15AM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights (GlobeNewswire) +5.11%
Feb-28-22 08:00AM	PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-03-22 08:00AM	PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-12-22 12:20PM	Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jan-06-22 08:00AM	PMV Pharma Announces Changes to its Board of Directors (GlobeNewswire) -16.31%
Dec-20-21 10:28AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Nov-22-21 08:00AM	PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference (GlobeNewswire)
Nov-12-21 07:15AM	PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-05-21 11:33AM	Pmv Pharmaceuticals Insider Trades $440K In Company Stock (Benzinga)
Sep-27-21 09:26PM	Goldman Sachs: Buy These 2 Stocks Before They Jump 40% (or More) (TipRanks)
Sep-09-21 08:00AM	PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development (GlobeNewswire)
Sep-02-21 08:00AM	PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-21 08:00AM	PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-19-21 06:19PM	Where Do Hedge Funds Stand On PMV Pharmaceuticals, Inc. (PMVP)? (Insider Monkey)
Jun-23-21 05:38AM	We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely (Simply Wall St.)
Jun-09-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference (GlobeNewswire)
Jun-03-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference (GlobeNewswire)
May-14-21 08:00AM	PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights (GlobeNewswire) +10.54%
May-05-21 08:00AM	PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-10-21 01:31PM	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021 (GlobeNewswire)
Apr-06-21 08:00AM	PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum (GlobeNewswire)
Mar-10-21 04:31PM	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021 (GlobeNewswire)
Mar-03-21 04:01PM	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-16-21 08:00AM	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board (GlobeNewswire) -9.57%
Dec-25-20 03:44AM	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn (Simply Wall St.)
Dec-16-20 03:19PM	Is PMVP A Good Stock To Buy Now? (Insider Monkey)
Nov-24-20 05:00PM	PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference (GlobeNewswire) +8.67%
Nov-23-20 08:00AM	PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 (GlobeNewswire)
Nov-13-20 08:00AM	PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights (GlobeNewswire) -5.50%
Oct-13-20 08:00AM	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation (GlobeNewswire)
Oct-09-20 03:41PM	Janus Henderson and PMV Pharmaceuticals See Activist Action (Barrons.com)
Oct-01-20 11:57AM	Biotech Pulmonx Shares Climb in Trading Debut (Barrons.com)
Sep-29-20 04:05PM	PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +5.00%
Sep-25-20 02:31PM	PMV Pharma Soars 115% as Biotech IPOs Take Off (Barrons.com)
12:37PM	PMV Pharmaceutical's stock nearly doubles in its debut (MarketWatch)
06:16AM	PMV Pharmaceuticals prices IPO at top end of expectations, raises $211.8 million (MarketWatch)
Sep-24-20 08:06PM	PMV Pharma Announces Pricing of Initial Public Offering (GlobeNewswire)

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	Nov 22 '23	Sale	2.23	87,786	195,763	0	Nov 24 04:38 PM
Mack David Henry	President and CEO	Oct 18 '23	Option Exercise	0.53	198,407	105,156	363,877	Nov 13 04:21 PM
Alland Leila	Chief Medical Officer	Sep 15 '23	Sale	6.62	6,291	41,646	45,909	Sep 18 04:22 PM
Jalota Deepika	Chief Development Officer	Sep 15 '23	Sale	6.62	4,104	27,168	29,946	Sep 18 04:26 PM
Mack David Henry	President and CEO	Aug 07 '23	Option Exercise	0.53	85,500	45,315	165,470	Aug 08 04:43 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ABEO

Abeona Therapeutics Inc

PMVP

PMV Pharmaceuticals Inc

Upgrade your FINVIZ experience